How much funding has Tinkeso Therapeutics raised?

Tinkeso Therapeutics has raised $600K in total funding, most recently a Venture Round.

Who are Tinkeso Therapeutics's investors?

Tinkeso Therapeutics's investors include IndieBio, SOSV.

When was Tinkeso Therapeutics founded?

Tinkeso Therapeutics was founded in 2016.

Where is Tinkeso Therapeutics headquartered?

Tinkeso Therapeutics is headquartered in Valhalla, United States.

What industry is Tinkeso Therapeutics in?

Tinkeso Therapeutics operates in Biotech, Healthcare.

How many employees does Tinkeso Therapeutics have?

Tinkeso Therapeutics has 1-10 employees.

Tinkeso Therapeutics

Advancing NKT cell therapies for cancers and autoimmune disorders

Valhalla, United States · Founded 2016 · $600K raised

Biotech

Healthcare

Headquarters: Valhalla
Employees: 1–10
Founded: 2016
Business Model: B2B

Website: tinkeso.com
Total Funding: $600K
Last Round: $600K Venture RoundSep 2024
Rounds: 1

About

Tinkeso Therapeutics (formerly Akeso Therapeutics) is an early-stage biotechnology company based in Valhalla, New York, dedicated to advancing Natural Killer T (NKT) cell therapies for the treatment of cancers and autoimmune disorders. Founded in 2016, the company's pipeline covers both native and engineered NKT cell therapies. Its lead asset, IMK-101, is an engineered invariant NKT (iNKT) cell therapy targeting several types of leukemia. Operating from BioInc@NYMC in Valhalla, Tinkeso aims to address unmet patient needs with off-the-shelf, allogeneic cell therapy solutions.

Summary

Tinkeso Therapeutics is a Biotech company based in Valhalla, United States, founded in 2016. It has raised $600K in total across 1 round, most recently a $600K Venture Round round in Sep 2024. Investors include IndieBio and SOSV.